Director/PDMR Shareholding

RNS Number : 3037U
GSK PLC
29 July 2022
 

GSK plc (the ' Company ')
Transaction notification


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2017 under the Company's 2017 Performance Share Plan and subject to a 2 year holding period.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

307,823.304






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2022-07-27

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan and subject to a 2 year holding period.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£17.6341

.

148,525.000






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2022-07-27

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSELFEUEESEEW

Companies

GSK (GSK)
UK 100

Latest directors dealings